Patents by Inventor Matthew Manning RIGGS

Matthew Manning RIGGS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122273
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Application
    Filed: November 1, 2024
    Publication date: April 17, 2025
    Applicant: MEREO BIOPHARMA 3 LIMITED
    Inventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS
  • Publication number: 20240400666
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Application
    Filed: May 20, 2024
    Publication date: December 5, 2024
    Applicant: MEREO BIOPHARMA 3 LIMITED
    Inventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS
  • Publication number: 20230365669
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 16, 2023
    Applicant: MEREO BIOPHARMA 3 LIMITED
    Inventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS
  • Publication number: 20210253687
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 19, 2021
    Inventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS
  • Publication number: 20190330322
    Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.
    Type: Application
    Filed: December 21, 2017
    Publication date: October 31, 2019
    Applicant: MEREO BIOPHARMA 3 LIMITED
    Inventors: Uwe JUNKER, Michaela KNEISSEL, Anthony Kent HALL, Rena Joy EUDY, Matthew Manning RIGGS